FacebookTwitterLinkedInContact UsLabrix.com


CME credits

Laboratory, Endocrine, & Neurotransmitter Symposium

September 14 - 16, 2018

Portland, OR

Gain additional clinical insight and treatment considerations to evaluate some of the most prevalent and challenging conditions that patients present with, including depression, anxiety, altered mental focus and stamina, sexual dysfunction, sleep disturbances, addictions and dependencies, weight management, and chronic disease. Early bird special extended through Sunday, August 26th. Save $50!


Wellness Wednesday

Webinar Series

Topic: Comprehensive Neurotransmitter Primer

September 5, 2018

Join Labrix clinical staff and special guests on the first Wednesday of every month at 9:30 AM and 12:00 PM PST. This free, live webinar series will cover a variety of neuroendocrine topics that will enhance your knowledge, with clinically applicable testing and treatment considerations.


Dallas, TX: September 6 - 9, 2018

Labrix will be in Texas for the IMMH conference next month. Come chat with our booth representative and learn more about testing with Labrix.


Phenylethlyamine (PEA):

a biomarker for ADHD


Published on 8/22/18

One of the newest analytes to Labrix neurotransmitter testing is Phenylethlyamine (PEA). Phenylalanine is the precursor amino acid which is converted to PEA via vitamin B6, an essential co-factor in the conversion to this primary trace amine. PEA is metabolically similar to amphetamine; when present in high quantities, it can exhibit stimulant effects.

The clinical implications of low PEA are many. Research suggests that it may play a role in depression and addiction. Decreased levels have been observed in patients with Parkinson’s disease and autism. Perhaps most notably, PEA levels are typically lower in people suffering from attention deficits. In fact, PEA is now considered a biomarker for ADHD.

Typically, the diagnosis of ADHD is done by analysis of symptoms. Recently, the American Psychiatric Association added PEA as a diagnostic biomarker for ADHD. They state, “This novel discovery will improve the confidence of the diagnostic efforts, possibly leading to reduced misdiagnosis and overmedication. Specifically, the urinary output of PEA was lower in a population of children suffering from ADHD, as compared to the healthy control population, an observation that was paralleled by reduced PEA levels in ADHD individuals.”

Because PEA was found to be lower in patients suffering from ADHD when compared to controls, measuring PEA can help to diagnose the disorder. Additionally, it has been observed that treatment with D-amphetamine and methylphenidate (Ritalin) to improve attentiveness will result in an increase in the secretion of PEA, suggesting that ADHD treatments normalize PEA levels. Outside of these medications, supplementation with the precursor amino acid L-phenylalanine, or PEA itself, can help to normalize levels and are not associated with significant side effects. 

If inattention is an issue for a patient of any age, consider the NeuroBasic profile which tests Serotonin, Dopamine, Norepinepherine, Epinephrine, Glutamate, GABA, Histamine, Glycine, and PEA. 



Baker GB, et al. Phenylethylaminergic mechanisms in attention-deficit disorder. Biol Psychiatry. 1991 Jan 1;29(1):15-22.

Irsdeld M, et al. B-phenyleyhylamine, a small molecule with a large impact. Webmedcentral. 2014. PMCID: PMC3904499

Kusaga A. Decreased beta-phenylethylamine in urine of children with attention deficit hyperactivity disorder and autistic disorder. No To Hattatsu 2002 May;34(3);243-8.

Scassellati C, et al. Biomarkers and attention-deficit/hyperactivity disorder: a systematic review and meta-analyses. J Am Acad Child Adolesc Psychiatry. 2012 Oct;51(10):1003-1019. 


The Anti-Anxiety Diet

by Ali Miller, RD, LD, CDE

As healthcare providers, we are often challenged to address lifelong anxiety in order to treat the underlying etiologies of HPA dysfunction, evaluated with the Labrix Adrenal Function Panel (salivary diurnal cortisol and DHEA).  This is no small task.  However, helping patients to identify thought patterns is an invaluable first step. 

Ali Miller, RD, LD, CDE is a food-as-medicine expert.  In her new book The Anti-Anxiety Diet, she explains her client assessments, ‘When in your silent mental space, are more of your thoughts focused on rumination of what was or anticipatory stress of what may be (the ever-loved “what ifs”)?‘  A brilliant inquiry, as many patients with chronic anxiety are not at all aware of their thought patterns and just how impactful these silent thoughts are on the HPA axis. Mindset shifts and subsequent HPA axis restoration forever remain elusive unless we can assist our patients in this discovery.

To learn more about Ali Miller’s functional approach to the treatment of anxiety, check out her new book, found here  www.alimillerrd.com/the-anti-anxiety-diet/.

*Click Image for Amazon link*


Disclaimer: All information given about health conditions, treatment, products, and dosages are for educational purposes only and do not constitute medical advice.